T1 Mapping in Cardiac Amyloidosis Can We Get There From Here?

The accurate identification of cardiac involvement in systemic light-chain (AL) amyloidosis is a critical aspect of clinical care. Mortality from cardiovascular causes is the most common cause of death in patients with AL amyloidosis, and those with cardiac involvement, seen in approximately 50% of patients with AL disease, are at the highest risk (1). Recognition of cardiac involvement informs clinical decisions regarding antiplasma cell therapy and heart failure management (2).